MedTrace Logo

Treatment of Diabetic Macular Edema With 0.5mg Intraocular Ranibizumab (Lucentis)

NCT01638858 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2014-07-08

No results posted yet for this study

Summary

In this prospective, open-label clinical study is to investigate the behavior of the retinal functions during development of diabetic macular disease (DME) under the influence of Lucentis. Measurements with the multifocal electroretinogram (ERG) and microperimetry is used here as an objective criteria to information about the retinal function obtain.

Conditions

  • Age-Related Macular Degeneration

Interventions

DRUG

Lucentis (Ranibizumab)

Ranibizumab Short- and Log-term Effects on Retinal Function measured by Multifocal-ERG and Microperimetry

Sponsors & Collaborators

  • University of Luebeck

    lead OTHER

Principal Investigators

  • Salvatore Grisanti, M.D. Prof. · University of Luebeck - Department of Ophthalmology: Germany

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-10-31
Primary Completion
2014-07-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01638858 on ClinicalTrials.gov